Murepavadin is the first in class of the outer membrane protein-targeting antibiotics (OMPTA) and a pathogen-specific peptidomimetic antibacterial with a novel, nonlytic mechanism of action targeting Pseudomonas aeruginosa. Murepavadin is being developed by Polyphor Ltd for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia. In preclinical studies, Murepavadin was highly effective against Pseudomonas aeruginosa, without evidence of generating resistance. Murepavadin has been evaluated in 8 clinical studies. Murepavadin penetrates into lung tissue and showed encouraging results in a Phase II study when given on top of standard of care in patients with Ventilator-Associated Bacterial Pneumonia. The phase III clinical trial was initiated in 2018 to assess the efficacy, safety, and tolerability of Murepavadin in adult subjects with ventilator-associated bacterial pneumonia. But in May 2019, Polyphor Ltd. suspended the global phase III trial for safety data review.

FLUDEOXYGLUCOSE is a fluorinated glucose analog. Its 18F radiolabelled form is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.